Antibody Therapies for Multiple Myeloma
Multiple Myeloma (MM) is characterized by the abberant proliferation and expansion of plasma cells in the Bone marrow. Despite the broad use of proteasome inhibitors and IMiDs, Multiple Myeloma remains an incurable disease. The introduction of Monoclonal antibodies, along with bi-specific antibodies...
Saved in:
Main Authors: | , , |
---|---|
Format: | Ebooks |
Published: |
IntechOpen,
2021-07-07.
|
Subjects: | |
Online Access: | Get Online |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Multiple Myeloma (MM) is characterized by the abberant proliferation and expansion of plasma cells in the Bone marrow. Despite the broad use of proteasome inhibitors and IMiDs, Multiple Myeloma remains an incurable disease. The introduction of Monoclonal antibodies, along with bi-specific antibodies and check point inhibitors, has significantly enhanced the armamentarium of available therapeutic options in the relapsed setting. The incorporation of the above-mentioned novel agents in triplet or quadruplet therapeutic regimens has led to significant prolongation of overall survival (OS) and progression free survival (PFS), without adding significant toxicity. Anti-CD38 monoclonal antibodies has become the cornerstone of antimyeloma therapy in both the newly diagnosed and relapsed setting. |
---|---|
Item Description: | https://mts.intechopen.com/articles/show/title/antibody-therapies-for-multiple-myeloma |